{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T02:44:48Z","timestamp":1782528288446,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,10]],"date-time":"2018-05-10T00:00:00Z","timestamp":1525910400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006098","name":"Radiological Society of North America","doi-asserted-by":"publisher","award":["Resident Research Grant"],"award-info":[{"award-number":["Resident Research Grant"]}],"id":[{"id":"10.13039\/100006098","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s10549-018-4808-9","type":"journal-article","created":{"date-parts":[[2018,5,10]],"date-time":"2018-05-10T06:21:35Z","timestamp":1525933295000},"page":"209-215","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Predictors of surveillance mammography outcomes in women with a personal history of breast cancer"],"prefix":"10.1007","volume":"171","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0840-7855","authenticated-orcid":false,"given":"Kathryn P.","family":"Lowry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lior Z.","family":"Braunstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos P.","family":"Economopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Salama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance D.","family":"Lehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Scott","family":"Gazelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elkan F.","family":"Halpern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine S.","family":"Giess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alphonse G.","family":"Taghian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janie M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,10]]},"reference":[{"key":"4808_CR1","unstructured":"Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER cancer statistics review, 1975\u20132014, National Cancer Institute, Bethesda, MD. \n                    https:\/\/seer.cancer.gov\/csr\/1975_2014\/\n                    \n                  , based on November 2016 SEER data submission, posted to the SEER web site, April 2017"},{"issue":"7","key":"4808_CR2","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1200\/JCO.2012.45.9859","volume":"31","author":"JL Khatcheressian","year":"2013","unstructured":"Khatcheressian JL et al (2013) Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31(7):961\u2013965","journal-title":"J Clin Oncol"},{"issue":"14","key":"4808_CR3","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1200\/JCO.2012.42.8375","volume":"30","author":"LE Schnipper","year":"2012","unstructured":"Schnipper LE et al (2012) American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol 30(14):1715\u20131724","journal-title":"J Clin Oncol"},{"key":"4808_CR4","unstructured":"National Comprehensive Cancer Network (2015) NCCN clinical practice guidelines in oncology: breast cancer (version 3.2014). \n                    http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf\n                    \n                  . Accessed 1 Jan 2015"},{"issue":"6","key":"4808_CR5","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1200\/JCO.2015.64.3809","volume":"34","author":"CD Runowicz","year":"2016","unstructured":"Runowicz CD et al (2016) American Cancer Society\/American Society of clinical oncology breast cancer survivorship care guideline. J Clin Oncol 34(6):611\u2013635","journal-title":"J Clin Oncol"},{"issue":"11S","key":"4808_CR6","first-page":"e43e52","volume":"13","author":"L Moy","year":"2016","unstructured":"Moy L et al (2016) ACR appropriateness criteria stage I breast cancer: initial workup and surveillance for local recurrence and distant metastases in asymptomatic women. J Am Coll Radiol 13(11S):e43\u2013e52","journal-title":"J Am Coll Radiol"},{"issue":"3","key":"4808_CR7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10549-008-0023-4","volume":"114","author":"WL Lu","year":"2009","unstructured":"Lu WL et al (2009) Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis. Breast Cancer Res Treat 114(3):403\u2013412","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"4808_CR8","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1093\/annonc\/mdp037","volume":"20","author":"N Houssami","year":"2009","unstructured":"Houssami N et al (2009) Early detection of second breast cancers improves prognosis in breast cancer survivors. Ann Oncol 20(9):1505\u20131510","journal-title":"Ann Oncol"},{"issue":"8","key":"4808_CR9","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1001\/jama.2011.188","volume":"305","author":"N Houssami","year":"2011","unstructured":"Houssami N et al (2011) Accuracy and outcomes of screening mammography in women with a personal history of early-stage breast cancer. JAMA 305(8):790\u2013799","journal-title":"JAMA"},{"issue":"5","key":"4808_CR10","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1158\/1055-9965.EPI-12-1208-T","volume":"22","author":"N Houssami","year":"2013","unstructured":"Houssami N et al (2013) Risk factors for second screen-detected or interval breast cancers in women with a personal history of breast cancer participating in mammography screening. Cancer Epidemiol Biomark Prev 22(5):946\u2013961","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"1","key":"4808_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1148\/radiol.2016161174","volume":"283","author":"CD Lehman","year":"2017","unstructured":"Lehman CD et al (2017) National performance benchmarks for modern screening digital mammography: update from the breast cancer surveillance consortium. Radiology 283(1):49\u201358","journal-title":"Radiology"},{"issue":"19","key":"4808_CR12","doi-asserted-by":"publisher","first-page":"10869","DOI":"10.1073\/pnas.191367098","volume":"98","author":"T Sorlie","year":"2001","unstructured":"Sorlie T et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869\u201310874","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"4808_CR13","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","volume":"22","author":"A Goldhirsch","year":"2011","unstructured":"Goldhirsch A et al (2011) Strategies for subtypes\u2013dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22(8):1736\u20131747","journal-title":"Ann Oncol"},{"issue":"8","key":"4808_CR14","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1093\/annonc\/mdv221","volume":"26","author":"AS Coates","year":"2015","unstructured":"Coates AS et al (2015) Tailoring therapies\u2013improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast cancer 2015. Ann Oncol 26(8):1533\u20131546","journal-title":"Ann Oncol"},{"issue":"9805","key":"4808_CR15","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1016\/S0140-6736(11)61539-0","volume":"378","author":"JS Reis-Filho","year":"2011","unstructured":"Reis-Filho JS, Pusztai L (2011) Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 378(9805):1812\u20131823","journal-title":"Lancet"},{"issue":"8","key":"4808_CR16","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMra0801289","volume":"360","author":"C Sotiriou","year":"2009","unstructured":"Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360(8):790\u2013800","journal-title":"N Engl J Med"},{"key":"4808_CR17","volume-title":"AJCC cancer staging manual","year":"2010","unstructured":"Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) (2010) AJCC cancer staging manual, 7th\u00a0edn. Springer, France","edition":"7"},{"issue":"29","key":"4808_CR18","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1200\/JCO.2011.36.1105","volume":"29","author":"ND Arvold","year":"2011","unstructured":"Arvold ND et al (2011) Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol 29(29):3885\u20133891","journal-title":"J Clin Oncol"},{"issue":"2","key":"4808_CR19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/tbj.12371","volume":"21","author":"LZ Braunstein","year":"2015","unstructured":"Braunstein LZ et al (2015) Outcome following local-regional recurrence in women with early-stage breast cancer: impact of biologic subtype. Breast J 21(2):161\u2013167","journal-title":"Breast J"},{"key":"4808_CR20","unstructured":"D\u2019Orsi CJ, Sickles EA, Mendelson EB, Morris EA et al (2013) ACR BI-RADS\u00ae atlas, breast imaging reporting and data system. American College of Radiology, Reston, VA"},{"key":"4808_CR21","unstructured":"D\u2019Orsi CJ, Mendelson EB, Ikeda DM et al (2003) Breast imaging reporting and data system: ACR BI-RADS\u2014breast imaging atlas. American College of Radiology, Reston, VA"},{"issue":"11","key":"4808_CR22","doi-asserted-by":"publisher","first-page":"14951502","DOI":"10.1001\/jamaoncol.2017.1256","volume":"3","author":"N Cho","year":"2017","unstructured":"Cho N, Han W, Han B, Bae MS, Ko ES, Nam SJ, Chae EY, Lee JW, Kim SH, Kang BJ, Song BJ, Kim E, Moon HJ, Kim SI, Kim SM, Kang E, Choi Y, Kim HH, Moon WK (2017) Breast cancer screening with mammography plus ultrasonography or magnetic resonance imaging in women 50 years or younger at diagnosis and treated with breast conservation therapy. JAMA Oncol 3(11), 1495\u20131502","journal-title":"JAMA Oncol"},{"issue":"3","key":"4808_CR23","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10549-013-2816-3","volume":"143","author":"HS Wirtz","year":"2014","unstructured":"Wirtz HS et al (2014) Factors associated with long-term adherence to annual surveillance mammography among breast cancer survivors. Breast Cancer Res Treat 143(3):541\u2013550","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"4808_CR24","doi-asserted-by":"publisher","first-page":"R3","DOI":"10.1186\/bcr3595","volume":"16","author":"L Domingo","year":"2014","unstructured":"Domingo L et al (2014) Tumor phenotype and breast density in distinct categories of interval cancer: results of population-based mammography screening in Spain. Breast Cancer Res 16(1):R3","journal-title":"Breast Cancer Res"},{"issue":"2","key":"4808_CR25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00432-012-1304-1","volume":"139","author":"A Caldarella","year":"2013","unstructured":"Caldarella A et al (2013) Biological characteristics of interval cancers: a role for biomarkers in the breast cancer screening. J Cancer Res Clin Oncol 139(2):181\u2013185","journal-title":"J Cancer Res Clin Oncol"},{"issue":"21","key":"4808_CR26","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1200\/JCO.2005.01.910","volume":"23","author":"SB Wedam","year":"2005","unstructured":"Wedam SB, Swain SM (2005) Contralateral breast cancer: where does it all begin? J Clin Oncol 23(21):4585\u20134587","journal-title":"J Clin Oncol"},{"issue":"7","key":"4808_CR27","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/jnci\/djh097","volume":"96","author":"SM Swain","year":"2004","unstructured":"Swain SM et al (2004) Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J Natl Cancer Inst 96(7):516\u2013523","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"4808_CR28","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/cncr.25587","volume":"117","author":"D Huo","year":"2011","unstructured":"Huo D et al (2011) Concordance in histological and biological parameters between first and second primary breast cancers. Cancer 117(5):907\u2013915","journal-title":"Cancer"},{"issue":"1","key":"4808_CR29","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10549-009-0469-z","volume":"120","author":"M Brown","year":"2010","unstructured":"Brown M, Bauer K, Pare M (2010) Tumor marker phenotype concordance in second primary breast cancer, California, 1999\u20132004. Breast Cancer Res Treat 120(1):217\u2013227","journal-title":"Breast Cancer Res Treat"},{"issue":"21","key":"4808_CR30","doi-asserted-by":"publisher","first-page":"4687","DOI":"10.1200\/JCO.2005.04.076","volume":"23","author":"G Arpino","year":"2005","unstructured":"Arpino G et al (2005) Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol 23(21):4687\u20134694","journal-title":"J Clin Oncol"},{"key":"4808_CR31","doi-asserted-by":"crossref","unstructured":"Lee JM et al (2015) Five-year risk of interval-invasive second breast cancer. J Natl Cancer Inst 107(7)","DOI":"10.1093\/jnci\/djv109"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-018-4808-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-018-4808-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-018-4808-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T07:48:25Z","timestamp":1557474505000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-018-4808-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,10]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["4808"],"URL":"https:\/\/doi.org\/10.1007\/s10549-018-4808-9","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,10]]},"assertion":[{"value":"25 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"EH is a research consultant for Hologic, Inc. and Real Imaging Ltd. GSG is a consultant for General Electric Healthcare. CDL serves on the Research Grant and Advisory Board for General Electric Healthcare. AGT is a consultant for VisionRT. JML receives a Research Grant from General Electric Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study complies with U.S. law. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}